Shares of biotech companies experienced volatility following the FDA’s reinstatement of Vinay Prasad, who had left amid controversy over drug approvals and social media criticism. Analysts are concerned that his return may exacerbate leadership instability and impact the agency’s drug approval consistency, particularly after recent turmoil involving Sarepta Therapeutics.
